Status: Recruiting
Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors
The purpose of this study is to determine if the experimental treatment with poly-ADP ribose polymerase (PARP) inhibitor, ACE-86225106 is safe, tolerable and has anti-cancer activity in adult patients with advanced solid tumors.
Participants needed: 298
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Acerand Therapeutics (Shanghai) LimitedUpdated: Dec 29, 2025Locations: 14
Eligibility criteria
Provide written informed consent; [+6]
Receiving any anti-cancer drugs, major surgery, extensive radiation therapy, or... [+13]